FDMT Q3 2019 Earnings — 4D Molecular Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

FDMT4D Molecular Therapeutics, Inc.

$427M

Q3 2019 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$540,000-88.1% YoY

Gross Profit

-$9M-1635.9% margin

Operating Income

-$17M-3152.4% margin

Net Income

-$17M-3088.0% margin

EPS (Diluted)

$-1.12

QoQ Revenue Growth

-75.5%

Cash Flow

Operating Cash Flow

-$11M

Free Cash Flow

-$12M

Stock-Based Comp.

$1M

Balance Sheet

Total Assets

$0

Total Liabilities

$0

Stockholders' Equity

$61M

Cash & Equivalents

-$73M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$540,000	$5M	-88.1%
Gross Profit	-$9M	-$546,500	-1516.5%
Operating Income	-$17M	-$3M	-572.6%
Net Income	-$17M	-$2M	-664.0%